| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 79 | 13.1x | 17.8x | Top tier | |
Growth | 30 | -1.4% | 7.1% | Bottom tier | |
Quality | 70 | 6.7% | 4.5% | Top tier | |
Safety | 49 | 6.1x | 2.6x | Around median | |
Capital Return | 37 | — | 2.12% | Bottom tier | |
Momentum | 12 | -21.2% | 2.9% | Bottom tier | |
Sentiment | 68 | 4 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Prestige Consumer Healthcare Inc. operates in consumer healthcare through a diversified portfolio of brands spanning eight categories following its recent acquisitions. Sales drivers include gastrointestinal products Dramamine and Fleet; skin care products Compound W and Dermal Therapy; eye and ear care products Clear Eyes, TheraTears, and Debrox; women’s health products Monistat and Summer’s Eve; and the wellness and sleep category led by Breathe Right. The company generates revenue by selling these products through retailers, e-commerce channels, and international markets.
In Q1 fiscal 2027, revenue reached $265.7 million, up 6.5% from $249.5 million, while organic growth was 3.2% after excluding currency effects and the Breathe Right acquisition. North America revenue increased 4.2% organically, while international revenue declined 2.1% organically due to the timing of distributor orders, and Breathe Right contributed approximately $5.9 million. Dramamine, Fleet, and Compound W led growth, while TheraTears and Debrox partly offset weakness in Clear Eyes, and e-commerce recorded strong double-digit consumer growth.
According to EDGAR data, gross profit was approximately $136.2 million in Q1 fiscal 2027, equivalent to a margin of about 51.3%, while net income reached $29.2 million and reported earnings per share were $0.61. On the adjusted basis presented by management, gross margin was approximately 55% and diluted earnings per share were $0.98, exceeding the analyst estimate of $0.89 and rising from $0.95 a year earlier, while adjusted EBITDA grew 5.5%. For comparison, in fiscal 2026 the company generated revenue of $1.1 billion, gross profit of $595.6 million, net income of $190.3 million, and earnings per share of $3.91.
Automated analysis for informational purposes only — not investment advice.
The analyst consensus is “Buy,” with an average target of $81.67 and a broad range of $66 to $93; the average target is approximately 14.9% above the top of the 52-week range of $71.07, while the highest target is approximately 30.9% above it. Conversely, the provided data do not offer a usable price-to-earnings multiple, and optimism in the targets must be weighed against net debt of approximately $2 billion, margin pressure, and the fact that the fiscal 2027 guidance increase came entirely from acquisitions.
Figures in the text are as of 2026-09-01; the live price is shown at the top of the page.
Revenue increased 6.5% to $265.7 million, and organic growth was 3.2% after excluding currency effects and the Breathe Right acquisition. Dramamine, Fleet, and Compound W led growth, while TheraTears and Debrox helped offset the decline in Clear Eyes. Adjusted diluted earnings per share were $0.98 on August 6, 2026, exceeding the analyst estimate of $0.89, while EDGAR filings showed net income of $29.2 million and earnings per share of $0.61.
Management expects Breathe Right and LaCorium to contribute approximately $190 million in fiscal 2027 revenue, raising the reported revenue range to $1.29–$1.315 billion. The adjusted diluted earnings per share range also increased to $4.55–$4.65, but management explained that both the revenue and earnings increases are entirely attributable to the two acquisitions. The organic growth outlook remained unchanged at 1% to 3%, and adjusted free cash flow is targeted at $270 million or more.
The Breathe Right portfolio is expected to generate approximately $200 million in annual revenue and contributed $5.9 million in Q1 fiscal 2027 after the transaction closed on June 12, 2026. Consumer awareness of the brand exceeds 90%, and its products are sold in more than 20 countries, including a strong presence in Western Europe, Australia, and Japan. Growth opportunities include Breathe Right Menthol, which was launched in 2025, and Breathe Right Sport, whose rollout began in fiscal 2027, along with digital marketing and international expansion.
Clear Eyes has declined substantially from its peak because of limited product availability and now represents less than 3% of sales following the addition of acquisition revenue. The company is investing in the Pillar5 facility, but it expects production variability to continue during the first half of fiscal 2027, including Q2. Management expects gradual improvement in facility stability and eye care shipments during the second half, although rebuilding safety stock, restoring the product assortment and shelf space, and renewing marketing will take several years.
Net debt was approximately $2 billion as of June 30, 2026, after financing Breathe Right with a seven-year term loan and using the financing together with cash to complete LaCorium on July 1, 2026. The company also issued $400 million in unsecured notes on July 15, 2026, to replace notes that were approaching maturity, moving its nearest maturities to 2031. Management is targeting adjusted free cash flow of at least $270 million and a leverage ratio slightly below four times by the end of fiscal 2027, with debt reduction prioritized during the year.
The increase in revenue and earnings per share guidance depends entirely on Breathe Right and LaCorium, while expected organic growth remained at 1% to 3%. Adjusted gross margin declined 120 basis points to approximately 55% in Q1 because of freight and mix, and the company faces assumed interest and amortization expenses of approximately $100 million and $33 million during the remainder of the year. Management also expects a modest organic decline in Q2 after retail order timing provided approximately two additional percentage points of growth to Q1, while Clear Eyes constraints and LaCorium integration risks persist.
